Latest filings (excl ownership)
8-K
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
18 Jun 24
424B5
Prospectus supplement for primary offering
18 Jun 24
424B5
Prospectus supplement for primary offering
17 Jun 24
8-K
Regulation FD Disclosure
13 Jun 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
13 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
14 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
1 Mar 24
8-K
Regulation FD Disclosure
7 Feb 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
UPLOAD
Letter from SEC
5 Dec 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
S-8
Registration of securities for employees
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
UroGen Pharma Reports Third Quarter 2023 Financial Results
14 Nov 23
EFFECT
Notice of effectiveness
18 Sep 23
CORRESP
Correspondence with SEC
13 Sep 23
UPLOAD
Letter from SEC
12 Sep 23
8-K
Departure of Directors or Certain Officers
11 Sep 23
S-3
Shelf registration
8 Sep 23
D
$120.00 mm in equity / options / securities to be acquired, sold $120.00 mm, 8 investors
14 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
10 Aug 23
ARS
2022 FY
Annual report to shareholders
1 Aug 23
DEFA14A
Additional proxy soliciting materials
1 Aug 23
DEF 14A
Definitive proxy
1 Aug 23
8-K
UroGen Announces $120 Million Private Placement of Ordinary Shares
27 Jul 23
8-K
Departure of Directors or Certain Officers
25 Jul 23
8-K
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
24 Mar 23
8-K
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
22 Mar 23
424B5
Prospectus supplement for primary offering
1 Dec 22
EFFECT
Notice of effectiveness
30 Nov 22
Latest ownership filings
SC 13G
COWEN AND COMPANY, LLC
24 Jun 24
SC 13G
Point72 Asset Management, L.P.
24 Jun 24
4
Mark Schoenberg
11 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
SC 13G/A
BlackRock Inc.
8 May 24
4
Mark Schoenberg
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
SC 13D/A
Arkin Moshe
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
MENORA MIVTACHIM HOLDINGS LTD.
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
4/A
Dong Kim
12 Feb 24
4/A
Dong Kim
12 Feb 24
4/A
Jason Drew Smith
5 Feb 24
4/A
Mark Schoenberg
5 Feb 24
4
Jason Drew Smith
2 Feb 24
4
Mark Schoenberg
2 Feb 24
4
Dong Kim
2 Feb 24
4
Elizabeth A. Barrett
2 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
29 Dec 23
SC 13G
GREAT POINT PARTNERS LLC
15 Sep 23
4
Arie Belldegrun
8 Sep 23
4
CYNTHIA M BUTITTA
8 Sep 23
4
Fred E Cohen
8 Sep 23
4
Daniel George Wildman
8 Sep 23
4
Stuart Holden
8 Sep 23
4
James A. Jr. Robinson
8 Sep 23
4
LEANA WEN
8 Sep 23
4
Jason Drew Smith
8 Sep 23
4
Dong Kim
8 Sep 23
4
Mark Schoenberg
8 Sep 23
4
Jason Drew Smith
5 Sep 23
SC 13D
Monograph Capital Holdings Advisors, LLC
4 Aug 23
4
Fred E Cohen
28 Jul 23
4/A
James A. Jr. Robinson
28 Jul 23